The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Ann Wan-Chin Ling,Cze-Ci Chan,Shao-Wei Chen,Yi-Wei Kao,Chien-Ying Huang,Yi-Hsin Chan,Pao-Hsien Chu

DOI: https://doi.org/10.1186/s12933-020-01162-w

IF: 8.949

2020-11-06

Cardiovascular Diabetology

Abstract:Abstract Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk of new-onset atrial fibrillation (AF) in T2DM patients is unclear. We aimed to evaluate the risk of new-onset AF associated with the use of SGLT2i compared to dipeptidyl peptidase-4 inhibitor (DPP4i) among a longitudinal cohort of diabetic patients. Methods We used medical data from a multi-center healthcare provider in Taiwan, which included a total of 15,606 and 12,383 patients treated with SGLT2i and DPP4i, respectively, from June 1, 2016 to December 31, 2018. We used propensity-score weighting to balance covariates across study groups. Patients were followed up from the drug index date until the occurrence of new-onset AF, discontinuation of the index drug, or the end of the study period, whichever occurred first. Results Overall, 55%, 45%, and 0% of the patients were treated with empagliflozin, dapagliflozin, and canagliflozin, respectively. Most patients in the DPP4i group were prescribed with linagliptin (51%), followed by sitagliptin (24%), saxagliptin (13%), vildagliptin (8%) and alogliptin (5%). The use of SGLT2i was associated with a lower risk of new-onset AF compared with DPP4i after propensity-score weighting [hazard ratio: 0.61; 95% confidential interval: 0.50–0.73; P < 0.001]. Subgroup analysis revealed that the use of SGLT2i was associated with a lower risk of new-onset AF compared with DPP4i across several subgroups including old age, female in gender, the presence of cardiovascular disease, hemoglobin A1c $$\ge$$ ≥ 8%, and chronic kidney disease. The advantage of SGLT2i over DPP4i persisted with different SGLT2i (dapagliflozin or empagliflozin) and either low- or standard-dose SGLT2i. Conclusions SGLT2i was associated with a lower risk of new-onset AF compared with DPP4i among T2DM patients in real-world practice.

cardiac & cardiovascular systems,endocrinology & metabolism

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate whether the use of sodium - glucose cotransporter 2 inhibitors (SGLT2i) can reduce the risk of new - onset atrial fibrillation (AF) compared with dipeptidyl peptidase - 4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM). Specifically, the study aims to compare the effects of these two drugs on new - onset atrial fibrillation through an observational cohort study, especially in Asian populations.

### Research Background
1. **The relationship between atrial fibrillation and diabetes**: Atrial fibrillation is one of the most common arrhythmias and is associated with an increased risk of ischemic stroke, hospitalization for heart failure, and death. The risk of atrial fibrillation in diabetic patients is 40% higher than that in the general population, and diabetes is also associated with multiple chronic diseases (such as obesity, hypertension, chronic kidney disease, and heart failure), which further increase the risk of atrial fibrillation.

2. **The mechanism of action of SGLT2i**: SGLT2i is a new type of antidiabetic drug that reduces blood glucose levels by inhibiting glucose reabsorption in the proximal renal tubules. In addition to its hypoglycemic effect, SGLT2i also has multiple insulin - independent beneficial effects, such as reducing blood pressure, body weight, urinary microalbumin, improving the lipid profile, arterial stiffness, and endothelial function. In addition, SGLT2i also shows significant cardioprotective and renoprotective effects and may help reduce the occurrence of atrial fibrillation.

3. **Limitations of previous studies**: Although some randomized controlled trials have demonstrated the benefits of SGLT2i in terms of cardiovascular end - point events, all - cause mortality, and hospitalization for heart failure, it is still unclear whether it can reduce the risk of atrial fibrillation. Therefore, this study aims to fill this knowledge gap, especially in a real - world setting.

### Research Objectives
The main objective of this study is to evaluate whether SGLT2i can reduce the risk of new - onset atrial fibrillation in patients with type 2 diabetes mellitus compared with DPP4i in a large real - world context. Specifically, the study focuses on:
- Comparing the differences in the risk of new - onset atrial fibrillation between SGLT2i and DPP4i.
- Analyzing the effects of SGLT2i in different subgroups (such as older age, female, a history of cardiovascular disease, HbA1c ≥ 8%, chronic kidney disease, etc.).
- Exploring the effects of different types of SGLT2i (such as dapagliflozin or empagliflozin) and different doses (low - dose or standard - dose).

Through these analyses, the study hopes to provide guidance for clinicians in choosing appropriate antidiabetic drugs to reduce the risk of atrial fibrillation.